Aliko Scientific automates CYTOfast to target recurring hospital revenue
Aliko Scientific (Ikonisys SA, listed on Euronext Growth Paris) announced on 12 November 2026 the upcoming launch of CYTOfast Auto, a fully automated version of its liquid-based cytology system, developed by its subsidiary Hospitex International.
The group's stated objective goes beyond the instrument itself: expanding its installed base in order to develop recurring revenue from reagents, consumables and services.
An automated platform designed for high-volume laboratories
The platform will be presented at the MEDICA 2026 trade fair, held in Düsseldorf from 16 to 19 November. The group presents it as a step in its expansion strategy towards high-volume hospital laboratories, public healthcare institutions and large-scale screening programmes.
CYTOfast Auto builds on the existing CYTOfast system and its proprietary Nephelometric Smart Technology, which analyses cell concentration to determine the sample volume required. The robotics add fully autonomous processing, continuous loading, prioritisation of urgent samples and automated traceability from sample to slide.
Francesco Trisolini, Chief Executive Officer of Aliko Scientific, stated: “By combining Hospitex's proven technology with advanced robotics, we are opening the door to new market segments, in particular public hospitals and large-scale screening programmes.”
Public tenders and consumables at the core of the targeted model
From a commercial standpoint, the group states its intention to strengthen its competitiveness in public hospital tenders and multi-year supply contracts. It also seeks to forge relationships with large private laboratory networks and international distributors, beyond the traditional customer base of the CYTOfast system.
The economic model relies on the continuous supply of proprietary reagents, consumables, maintenance and technical services. According to the group, expanding the installed base of instruments should create opportunities for long-term customer relationships and provide better revenue visibility.
To support this orientation, the company cites data from Grand View Research: the global cytology segment was valued at approximately $15.3 billion in 2024 and could reach $38.2 billion by 2030. This corresponds to a compound annual growth rate of 16.6% over the 2025-2030 period.
According to the same source, the broader histology and cytology market represented $24.3 billion in 2025. Consumables and reagents accounted for approximately 59.7% of it, a proportion that illustrates the weight of the recurring sales on which the group's strategy relies.
